As it is known, the DLBCL is dependent on BCR signaling, thus pathways activated by this receptor might be targeted to obtain a better response in some DLBCL subtypes, including PCNSL [40]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.